Skip to content

The Effect of Multiple Medications on the Incidence of Organic Dyspepsia

The Effect of Multiple Medications on the Incidence of Organic Dyspepsia:a Prospective Observational Cohort

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05524675
Enrollment
500
Registered
2022-09-01
Start date
2022-06-01
Completion date
2024-06-01
Last updated
2022-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspepsia

Brief summary

Dyspepsia is a very common gastrointestinal disease, presented as predominant symptom of upper abdominal pain. Underlying causes for dyspepsia can classified as organic or functional dyspepsia. Some medications (eg. non-steroid anti-inflammatory drugs (NSAIDs)) were associated with higher frequent incidences of organic lesions. Multiple medications showed an increased trend with aging of the population and multimorbidity. Multiple medications were suggested to be strongly relate to adverse drug events (ADEs), adverse drug reactions (ADRs), drug-drug interactions, and drug-disease interactions, which had been reported to lead to higher incidences of some diseases, including fractures, cognitive impairment and malnutrition. However, it was unknown if multiple medications was associated with more incidences of organic dyspepsia.

Interventions

None listed

Sponsors

Air Force Military Medical University, China
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. aged ≥18 years old 2. patients who met broad criteria of dyspepsia 3. undergoing upper endoscopy and abdominal ultrasonography within one year.

Exclusion criteria

1. organ failure defined by Marshall standard 2. severe psychiatric illnesses 3. suspected or identified bowel obstruction 4. known malignancy 5. pregnancy or lactation 6. unable to provide consent

Design outcomes

Primary

MeasureTime frameDescription
the rate of patients diagnosed with organic upper gastrointestinal (GI) diseases.1 dayAll included patients underwent upper GI endoscopy and abdominal ultrasound and H. Pylori test. Barrett's esophagus, esophageal candidiasis, esophageal cancer, gastric ulcer, gastric erosion, gastric cancer, duodenal ulcer, duodenal erosion, cholecystitis, pancreatitis and biliary stones were classified as organic upper GI diseases.

Secondary

MeasureTime frameDescription
Number of participants with different subtypes of functional dyspepsia6 monthsFunctional dyspepsia was based on Rome IV criteria, which was based on symptom and duration rather than scores. Functional dyspepsia was classified into three subgroups:(1) Postprandial Distress Syndrome, Must include one or both of the following at least 3 days per week: 1. Bothersome postprandial fullness (ie, severe enough to impact on usual activities) 2. Bothersome early satiation (ie, severe enough to prevent finishing a regular-size meal) (2) Bothersome epigastric pain, Must include at least 1 of the following symptoms at least 1 day a week: 1. Bothersome epigastric pain (ie, severe enough to impact on usual activities) AND/OR 2. Bothersome epigastric burning (ie, severe enough to impact on usual activities). (3) mixed syndrome, defined when postprandial distress syndrome and epigastric pain syndrome presented simultaneously
Short Form of Nepean Dyspepsia Index (SF-NDI)1 dayThe SF-NDI consists of 10 questions regarding the effects of dyspepsia symptoms (stomach problems) on different aspects of life (tension, interference with daily activities, eating/drinking, knowledge/control, and work/study). Each response can be from 1 (not at all affected) to 5 (extremely affected), or 0 (N/A), for a total summed score out of 50.
Hospital anxiety scale1 dayAnxiety of patients are assessed by using Hospital Anxiety Scale.It contains 7 items, which assess symptoms experienced during the past week on a 0-3 scale. A subscore of \> 8 for anxiety would indicate a clinical case.
Functional dyspepsia6 monthsFunctional dyspepsia was defined by Rome IV criteria, which was based on symptom and duration rather than scores. Patients diagnosed as Rome IV criteria met one or more of following criteria: postprandial fullness, early satiation, epigastric pain, and epigastric burning that are unexplained after a routine clinical evaluation, Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis. the above symptoms and durations were included in the questionaire. Physiological parameter was not required for Rome IV criteria.
Quality of Life scores1 dayQuality of Life scores assessed by Patient-reported outcomes measurement information system (PROMIS) Global-10 questionnaire.PROMIS Global-10 is a newly validated 10-question survey used to assess health care-related quality of life measures for the general population. It's a 10-item patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales. These scores are then standardized to the general population, using the T-Score. The average T-Score for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient and a better quality of life.
Severity of functional dyspepsia judged by patients1 dayPatients rated the severity of functional dyspepsia as mild, moderate, and severe by themselves.
Number of participants with other functional gastrointestinal diseases1 dayOther functional gastrointestinal diseases#such as irritable bowel syndrome(IBS) or functional heartburn#etc.
Hospital depression scale1 dayDepression of patients are assessed by using Hospital Depression Scale. It contains 7 items, which assess symptoms experienced during the past week on a 0-3 scale. A score of \> 8 for depression would indicate a clinical case.

Countries

China

Contacts

Primary ContactYanglin Pan
yanglinpan@hotmail.com13991811225

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026